Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study

Study Summary

The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.

Interventions

Study Locations

Facility	City	State	Country
Reed Neurological Research Center	Los Angeles	California	United States
UCLA Children's Heart Center	Los Angeles	California	United States
UCLA Clinical Lab Services	Los Angeles	California	United States
UCLA Kameron Gait and Motion Analysis Laboratory (Westwood Rehabilitation Center)	Los Angeles	California	United States
UCLA Medical Center	Los Angeles	California	United States
Duke Lenox Baker Children's	Durham	North Carolina	United States
Duke Children's Health Center	Durham	North Carolina	United States
University of Utah Imaging and Neurosciences Center	Salt Lake City	Utah	United States
University of Utah Hospital	Salt Lake City	Utah	United States
Primary Children's Hospital	Salt Lake City	Utah	United States
University of Utah Clinical Neurosciences Center	Salt Lake City	Utah	United States
University of Utah Craig H. Neilsen Rehabilitation Hospital	Salt Lake City	Utah	United States

Official Trial Information

View on ClinicalTrials.gov